Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Essa Pharma (EPIX)

Essa Pharma (EPIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Newswire.ca - Thu Oct 31, 7:57PM CDT

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to...

EPIX : 1.7300 (-0.57%)
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress Newswire.ca - Fri Sep 13, 4:19PM CDT

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...

EPIX : 1.7300 (-0.57%)
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference Newswire.ca - Wed Sep 11, 3:05PM CDT

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment...

EPIX : 1.7300 (-0.57%)
ESSA Pharma: Fiscal Q3 Earnings Snapshot AP - Mon Aug 5, 6:03AM CDT

ESSA Pharma: Fiscal Q3 Earnings Snapshot

EPIX : 1.7300 (-0.57%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 Newswire.ca - Mon Aug 5, 6:00AM CDT

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the...

EPIX : 1.7300 (-0.57%)
ESSA Pharma to Present at the JonesHealthcare Seaside Summit Newswire.ca - Mon Jul 8, 3:05PM CDT

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7300 (-0.57%)
ESSA Pharma to Present at the Jefferies Global Healthcare Conference Newswire.ca - Thu May 30, 7:00AM CDT

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7300 (-0.57%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 Newswire.ca - Tue May 14, 6:00AM CDT

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...

EPIX : 1.7300 (-0.57%)
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Newswire.ca - Tue Apr 9, 7:00AM CDT

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7300 (-0.57%)
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Newswire.ca - Thu Mar 7, 7:13PM CST

/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7300 (-0.57%)

Barchart Exclusives

1 Warren Buffett Stock to Buy on the Dip Barchart - 3 minutes ago
This longtime Buffett holding is down about 15% since setting its all-time highs in September, and looks like a bargain buy in this market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot